According to the globalmammalian polyclonal IgG antibody market reportby IMARC Group, the market reached a value of US$ 1,038.2 Million in 2022, and it is projected to reach a value of US$ 1,415.3 Million by 2028, exhibiting a CAGR of 5.2% during 2023-2028.
How Big Is The Mammalian Polyclonal IgG Antibody Market?
The global mammalian polyclonal IgG antibody market size reached US$ 1,038.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,415.3 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.
What are Mammalian Polyclonal IgG Antibody?
Mammalian polyclonal immunoglobulins (IgG) antibody represents antigens or vaccinations manufactured through inoculation of various mammals, such as rabbits, mice, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG.
These antibodies are used in labeling reagents in several immunoassay trials, including western blot tests, enzyme-linked immunosorbent assay (ELISA), immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Mammalian polyclonal IgG antibody is commercially available in cardiac, metabolic, and renal marker variants. It assists in creating multiple therapeutics, diagnosing various ailments, and performing identification and flow cytometry.
As a result, mammalian polyclonal IgG antibody finds widespread applications in biochemical research to detect denatured proteins and study diseases and their treatments.
Request For A Free Sample Copy Of This Report:https://www.imarcgroup.com/mammalian-polyclonal-igg-antibody-market/requestsample
What Are The Growth Prospects And Trends In The Mammalian Polyclonal IgG Antibody Industry?
The escalating prevalence of several chronic disorders, such as cancer and autoimmune ailments, and the rising demand for antigens for multiple immunoassay tests and therapeutic and analytical applications in research settings are among the primary factors driving the mammalian polyclonal IgG antibody market.
Besides this, the increasing investments in biotechnology and pharmaceutical companies to formulate effective novel vaccinations and injectables through advanced technologies are further augmenting the market growth. Moreover, the continuous innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is catalyzing the global market.
Apart from this, the expanding healthcare infrastructure and the extensive research and development (RD) activities to enhance antigen efficacy are acting as significant growth-inducing factors.Furthermore, the elevating requirement for biomarkers by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia is expected to bolster the mammalian polyclonal IgG antibody market in the coming years.
What Is Included In Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Type:
- Goat
- Rabbit
- Horse
- Mouse
- Others
Breakup by Product:
- Cardiac Markers
- Metabolic Markers
- Renal Markers
- Others
Breakup by Application:
- ELISA
- Immunoturbidimetry
- Immunoelectrophoresis
- Antibody Identification
- Immunohistochemistry
- Immunocytochemistry
- Western Blotting
Breakup by End Use:
- Hospitals
- Diagnostic Centers
- Academic and Research Institutes
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Abbiotec Inc.
- Abcam plc
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- Creative Diagnostics
- Elabscience Biotechnology Inc.
- Geno Technology Inc.
- Merck KGaA
- Proteintech Group Inc.
- STEMCELL Technologies Inc.
- and Thermo Fisher Scientific Inc.
Ask Analyst For Customization And Browse Full Report With TOC List Of Figure:https://www.imarcgroup.com/mammalian-polyclonal-igg-antibody-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Groups information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email:sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn:https://www.linkedin.com/company/imarc-group/mycompany/
